Long-Acting Insulin Tresiba Gains Pediatric Indication

Treatment Insulin
1

Good news for parents who have wanted to try Tresiba.

http://www.empr.com/news/long-acting-insulin-tresiba-gains-pediatric-indication/article/580155/

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an expanded use for Tresiba (insulin degludec) injection to improve glycemic control in children and adolescents with both type 1 and type 2 diabetes.

Tresiba, a long-actin insulin, was initially approved in September 2015 to improve glycemic control in adults with type 1 or type 2 diabetes mellitus. This expanded approval makes Tresiba the only basal insulin for use in diabetes patients as young as age 1.

4 Likes
2

Great news! I sincerely hope it’ll make lives for a lot of these children (and their parents) easier and healthier

3

Yay!

4

Here’s the Novo-Nordisk press-release. It shows a limitation that the patient must be taking at least five units of Tresiba per day.

5

Heh… that just means it has to be prescribed as such…

6

what were patients so young using before tresiba then? if it is the only basal insulin for use in patients as young as 1?

7

It is not the only basal insulin for use in patients as young as 1. Where did you hear that?